Idorsia to develop daridorexant for autism spectrum disorder
Idorsia will start a new daridorexant development program in autism spectrum disorder after unexpected Phase 2 findings; details due in H1 2027.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swiss company Idorsia said it will pursue a new development program for daridorexant in autism spectrum disorder (ASD). The decision follows unexpected results from a Phase 2 study in children with insomnia disorder: beyond better sleep, the 50 mg dose showed improvements in affect, behavior, cognition and daily activities among participants with ASD or subthreshold ASD traits.
The company is discussing the program design, including doses, with health authorities and is developing a dedicated formulation. Further details are expected in the first half of 2027.
why it matters
For Idorsia this opens a new research avenue, but the market impact looks limited for now. Until the effect is confirmed in dedicated trials, the news is unlikely to move the company's valuation materially; investors may watch regulatory talks and first program data.
market impact
Idorsia: new development avenue, effect on valuation still uncertain
tags
instruments
sources
- Idorsia Says To Advance Development In Autism Spectrum Disorder — Reuters, 26 October 2026 at 06:01 UTC
- A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder — globenewswire.com, 26 October 2026 at 06:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗